CHO-K1/Human PAR4 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0206A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The PAR4 receptor (Protease-Activated Receptor 4) is a G protein-coupled receptor primarily activated by thrombin (at low concentrations) and trypsin, belonging to the protease-activated receptor family. It is expressed in human platelets, vascular endothelial cells, gastrointestinal tract, skeletal muscle, lungs, and the central nervous system. Its core function involves mediating thrombin signaling to induce platelet aggregation and cytoskeletal rearrangement via Gq and G12/13 pathways, playing a critical role in thrombosis, vascular permeability regulation, and inflammatory responses. Unlike PAR1, PAR4 requires higher thrombin concentrations for activation, thus primarily contributing to sustained coagulation signaling and emerging as a novel target for antithrombotic therapy.
Screeningbio’s CHO-K1/Human PAR4 cell line overexpress F2RL3 receptor and is designed to detect increases in intracellular IP-1 levels in response to agonist stimulation of the receptor. Cisbio HTRF IP-1 kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | F2RL3 |
Accession Number | NM_003950 |
Parental Line | CHO-K1 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The PAR4 receptor (Protease-Activated Receptor 4) is a G protein-coupled receptor primarily activated by thrombin (at low concentrations) and trypsin, belonging to the protease-activated receptor family.
It is expressed in human platelets, vascular endothelial cells, gastrointestinal tract, skeletal muscle, lungs, and the central nervous system. Its core function involves mediating thrombin signaling to induce platelet aggregation and cytoskeletal rearrangement via Gq and G12/13 pathways, playing a critical role in thrombosis, vascular permeability regulation, and inflammatory responses.
Unlike PAR1, PAR4 requires higher thrombin concentrations for activation, thus primarily contributing to sustained coagulation signaling and emerging as a novel target for antithrombotic therapy.